CTOs on the Move

MSI

www.methylationsciences.com

 
MSI Methylation Sciences Inc. (“MSI”) is a clinical-stage pharmaceutical company focused on developing new products based on molecules which have clinical proof of concept but which have yet to be exploited in the major pharmaceutical markets. MSI`s focus is in the CNS space where clinical proof of concept is key to reducing the drug development risk. Our lead product candidate, Strada™, is based upon Ademetionine, a naturally occurring molecule produced throughout the body, where it plays a vital role in the one-carbon cycle. Our disease indication is Major Depressive Disorder (MDD).
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

MSI raised $30M on 10/07/2016

Similar Companies

Siegfried USA

Siegfried USA is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Pennsville, NJ. To find more information about Siegfried USA, please visit www.siegfried-usa.com

MEDZONE

MEDZONE Inc. is a Montreal, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Witham Health Services

Witham Health Services is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Witham Health Services is based in Lebanon, IN. You can find more information on Witham Health Services at www.witham.org

Holiday Retirement

Holiday Retirement is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Salem, OR. To find more information about Holiday Retirement, please visit www.holidaytouch.com

ForSight VISION5

ForSight VISION5, Inc. (www.forsightvision5.com), was founded in January of 2011 as the fifth company to emerge from the ophthalmic incubator ForSight Labs, LLC (www.forsightlabs.com). ForSight VISION5 is focused on developing non-invasive drug delivery products that replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy. ForSight VISION5`s lead product candidate is the Helios insert, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to receive medication continually. The Helios insert is restricted to investigational use only and has not been approved by the Food and Drug Administration or any other regulatory authority for commercial distribution.